divalproex sodium NDC 70518-1749

NDC codes

FDA NDC Directory

Product NDC (as listed)70518-1749Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70518-1749Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70518-1749-1	70518174901	100 POUCH in 1 BOX (70518-1749-1) / 1 CAPSULE, COATED PELLETS in 1 POUCH (70518-1749-0)Marketed from Dec 17, 2018

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): divalproex sodium
Generic name (nonproprietary): divalproex sodium
Active ingredients: Divalproex sodium — 125 mg/1
Dosage form: Capsule, Coated pellets
Route: Oral
Labeler: REMEDYREPACK INC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 078919
Marketing start: Dec 17, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 70518-1749_50aee7c6-5343-9d1f-e063-6294a90ad72cSPL ID 50aee7c6-5343-9d1f-e063-6294a90ad72cSPL set ID ab8616a5-ea72-4df7-b095-54ea19ef6fbaRxCUI 1099596UNII 644VL95AO6
Pharmacologic class: Anti-epileptic Agent; Mood Stabilizer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470518174901 followed by a unit qualifier and the quantity

Package 70518-1749-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 30, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Divalproex sodium delayed-release capsules are an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Divalproex sodium delayed-release capsules are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures. Divalproex sodium delayed-release capsules are also indicated for use as sole and adjunctive therapy in the treat…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 078919

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 078919
Product	Strength	Form · route	Labeler	Product NDC
Divalproex Sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	American Health Packaging	68084-313
Divalproex Sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	Cardinal Health 107, LLC	55154-4759
divalproex sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	Zydus Pharmaceuticals USA Inc.	68382-106
divalproex sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	ATLANTIC BIOLOGICALS CORP.	17856-0109
divalproex sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	Zydus Lifesciences Limited	65841-639